|
1
|
Basu S, Nachat-Kappes R, Caldefie-Chézet F
and Vasson MP: Eicosanoids and adipokines in breast cancer: from
molecular mechanisms to clinical considerations. Antioxid Redox
Signal. 18:323–360. 2013. View Article : Google Scholar
|
|
2
|
Bray F, Jemal A, Grey N, Ferlay J and
Forman D: Global cancer transitions according to the Human
Development Index (2008–2030): a population-based study. Lancet
Oncol. 13:790–801. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Børresen AL: Role of genetic factors in
breast cancer susceptibility. Acta Oncol. 31:151–155. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bishop DT: The involvement of genetic
factors in susceptibility to breast cancer. Eur J Cancer Prev.
2(Suppl 3): 125–130. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mavaddat N, Antoniou AC, Easton DF and
Garcia-Closas M: Genetic susceptibility to breast cancer. Molr
Oncol. 4:174–191. 2010. View Article : Google Scholar
|
|
6
|
Nickels S, Truong T, Hein R, et al:
Evidence of gene-environment interactions between common breast
cancer susceptibility loci and established environmental risk
factors. PLoS Genet. 9:e10032842013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Czerska K, Nawara M and Bal J: I. Single
nucleotide polymorphism in human genetic analyses. Med Wieku
Rozwoj. 7:531–546. 2003.In Polish.
|
|
8
|
Erichsen HC and Chanock SJ: SNPs in cancer
research and treatment. Br J Cancer. 90:747–751. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang N, Li X, Tao K, et al: BCL-2 (-938C
> A) polymorphism is associated with breast cancer
susceptibility. BMC Med Genet. 12:482011. View Article : Google Scholar :
|
|
10
|
Romanowicz-Makowska H, Bryś M, Forma E, et
al: Single nucleotide polymorphism (SNP) Thr241Met in the XRCC3
gene and breast cancer risk in Polish women. Pol J Pathol.
63:121–125. 2012.PubMed/NCBI
|
|
11
|
Popescu NC and Goodison S: Deleted in
liver cancer-1 (DLC1): an emerging metastasis suppressor gene. Mol
Diagn Ther. 18:293–302. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamaga M, Kawai K, Kiyota M, Homma Y and
Yagisawa H: Recruitment and activation of phospholipase C
(PLC)-delta1 in lipid rafts by muscarinic stimulation of PC12
cells: contribution of p122RhoGAP/DLC1, a tumor-suppressing
PLCdelta1 binding protein. Adv Enzyme Regul. 48:41–54. 2008.
View Article : Google Scholar
|
|
13
|
Shih YP, Liao YC, Lin Y and Lo SH: DLC1
negatively regulates angiogenesis in a paracrine fashion. Cancer
Res. 70:8270–8275. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou X, Thorgeirsson SS and Popescu NC:
Restoration of DLC-1 gene expression induces apoptosis and inhibits
both cell growth and tumorigenicity in human hepatocellular
carcinoma cells. Oncogene. 23:1308–1313. 2004. View Article : Google Scholar
|
|
15
|
Zheng SL, Mychaleckyj JC, Hawkins GA, et
al: Evaluation of DLC1 as a prostate cancer susceptibility gene:
mutation screen and association study. Mutat Res. 528:45–53. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dong X, Zhou G, Zhai Y, et al: Association
of DLC1 gene polymorphism with susceptibility to hepatocellular
carcinoma in Chinese hepatitis B virus carriers. Cancer
Epidemiology. 33:265–270. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Suzuki Y, Saito R, Zaraket H, Dapat C,
Caperig-Dapat I and Suzuki H: Rapid and specific detection of
amantadine-resistant influenza A viruses with a Ser31Asn mutation
by the cycling probe method. J Clin Microbiol. 48:57–63. 2010.
View Article : Google Scholar :
|
|
18
|
Temin HM: Evolution of cancer genes as a
mutation-driven process. Cancer Res. 48:1697–1701. 1988.PubMed/NCBI
|
|
19
|
Zheng W, Long J, Gao YT, et al:
Genome-wide association study identifies a new breast cancer
susceptibility locus at 6q25.1. Nat Genet. 41:324–328. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yuan BZ, Miller MJ, Keck CL, Zimonjic DB,
Thorgeirsson SS and Popescu NC: Cloning, characterization, and
chromosomal localization of a gene frequently deleted in human
liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res.
58:2196–2199. 1998.PubMed/NCBI
|
|
21
|
Zhou X, Zimonjic DB, Park SW, Yang XY,
Durkin ME and Popescu NC: DLC1 suppresses distant dissemination of
human hepatocellular carcinoma cells in nude mice through reduction
of RhoA GTPase activity, actin cytoskeletal disruption and
down-regulation of genes involved in metastasis. Int J Oncol.
32:1285–1291. 2008.PubMed/NCBI
|
|
22
|
Ullmannova V and Popescu NC: Expression
profile of the tumor suppressor genes DLC-1 and DLC-2 in solid
tumors. Int J Oncol. 29:1127–1132. 2006.PubMed/NCBI
|
|
23
|
Xie CR, Sun HG, Sun Y, et al: Significance
of genetic variants in DLC1 and their association with
hepatocellular carcinoma. Mol Med Rep. 12:4203–4209.
2015.PubMed/NCBI
|
|
24
|
Dai X, Li L, Liu X, Hu W, Yang Y and Bai
Z: Cooperation of DLC1 and CDK6 affects breast cancer clinical
outcome. G3 (Bethesda). 5:81–91. 2014.
|
|
25
|
Lee PH and Shatkay H: F-SNP:
computationally predicted functional SNPs for disease association
studies. Nucleic Acids Res. 36:D820–D824. 2008. View Article : Google Scholar :
|
